

Statement from Novo Nordisk Ireland Limited on the supply of Novo Nordisk products to Ireland post Brexit

Dublin, Ireland, 25 January 2019 - In light of continued uncertainty around Brexit and the future relationship of the UK with the European Union, Novo Nordisk Ireland wish to inform patients using our medicinal products that we have taken steps to ensure continuity of supply regardless of the outcome.

All of our medicinal products come from continental Europe and currently these arrive in Ireland via the UK land-bridge. To ensure continuity of supply and avoid delays which may occur with the transit of medicinal products through the UK after 29th March, Novo Nordisk plan to ship all medicinal products directly to Ireland.

We therefore advise patients taking Novo Nordisk medicines to continue to access their prescribed medicines as they normally do.

About Novo Nordisk

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 42,000 people in 77 countries and markets its products in more than 165 countries. For more information, visit novonordisk.com, [Facebook](#), [Twitter](#), [LinkedIn](#), [YouTube](#)

For queries or further information please contact us:

Clinical, Medical and Regulatory 1850 665 665
department

infoireland@novonordisk.com

IE19NNG00001; Date of preparation: January 2019
The Apis bull logo is a registered trademark of Novo Nordisk A/S

Novo Nordisk Limited

First Floor, Block A
The Crescent Building
Northwood Business Park
Santry, Dublin 9
D09 X8W3
Ireland

Telephone:
+353 1 862 9700
Facsimile:
+353 1 862 9725

E-mail:
infoireland@novonordisk.com
Internet:
www.novonordisk.ie

Registration No.:
61378

VAT No. 4510223A